Merck stock popped Wednesday on the back of positive test results for a new treatment combo in a common form of lung cancer.

Many think the next standard cancer treatment will pair two innovations.

Three hours inland from Chennai, India, traffic crawls on a half-finished road past rice fields and cow crossings until it reaches a newer complex of neat white buildings. Among them is the cancer ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

The F.D.A. approved Merck’s injected version of its blockbuster infusion Keytruda. The company says it will be quicker and easier, but it stands to slow the adoption of cheaper competitors and ...

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the U.S. drugmaker’s anti-PD-1 therapy in a ...

The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug Summit Therapeutics and Akeso shared more data for their experimental lung-cancer drug ...

Median overall survival for ivonescimab was 17.0 months vs. 14.0 months for placebo in Western patients. Ivonescimab plus chemo cut progression risk by 33% in Western patients and 45% in Chinese ...

A promising new cancer drug helped reduce the risk of death by 34% in patients with the most common form of lung cancer, but investors had a lukewarm response to the data. The highly anticipated ...

This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. Oncology drug development is no longer a singles market as ...